Table 2 Patient demographics
From: The improvement of motor symptoms in Huntington’s disease during cariprazine treatment
Participant | Sex | Age | Disease duration | TFC | CAR dose (mg/day) | Tetrabenazine dose (mg) |
|---|---|---|---|---|---|---|
P1 | M | 42 | 4 | 10 | 1.5 | 2 × 25 |
P2 | F | 48 | 1 | 10 | 1.5 | 3 × 25 |
P3 | F | 51 | 4 | 10 | 1.5 | 3 × 7.5 |
P5 | F | 50 | 6 | 12 | 3 | |
P6 | F | 36 | 6 | 10 | 1.5 | 4 × 25 |
P7 | F | 40 | 0.5 | 15 | 4.5 | |
P8 | F | 53 | 1 | 5 | 1.5 | 2 × 12.5 |
P9 | M | 74 | 8 | 6 | 1.5 | 3 × 25 |
P10 | F | 43 | 1 | 6 | 1.5 | |
P11 | M | 55 | 10 | 1 | 1.5 | 4 × 25 |
P12 | F | 42 | 1 | 10 | 1.5 | 3 × 12.5 |
P13 | F | 66 | 4 | 8 | 1.5 | 3 × 7.5 |
P14 | F | 43 | 4 | 5 | 1.5 | 3 × 50 |
P15 | M | 42 | 2 | 12 | 1.5 | |
P16 | F | 37 | 1 | 12 | 1.5 |